tbuckley/cabot-search huggingface dataset:
AB0862 Articular and Extra-Articular Damage in Patients with Juvenile Idiopathic Arthritis
Authors: D. Dalia, N.E. Carmen, M.E. Aritina, P. Ileana
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> The objective of this study was to asses the damage present in patients with JIA using the JADI-A and JADI-E scores, as well as their correlation to various clinical, lab and functional parameters. <h3>Methods</h3> The study was prospective and it took place between 2009 and 2014, involving 45 Romanian patients with JIA:15 patients with the systemic form, 15 patients with the polyarticular form and 15 patients with the oligoarticular form, in which the clinical, lab and radiological factors at the onset of the disease were assessed. The reevaluation of the patients was done 3 years later, following a special protocol that included the assessment of the general state, the disease activity score (DAS 28), joint involvement, radiological modifications (according to the Dale scoring system), CHAQ, the JADI-A and JADI-E scores. The correlation between the JADI scores and other parameters was made with the help of Spearman9s correlation coefficient. <h3>Results</h3> The articular damage highlighted by the JADI-A score was present in 15 patients (33.33%). Extra-articular damage was present in 24 patients (53.33%) and the most affected form was the systemic one – 12 patients (80%). The most frequent extra-articular impairment was growth hypotrophy, which was present in 15 patients (33.33%). In the entire subject group of patients with JIA, the JADI-A score is correlated (p&lt;0.01) with the articular score (0.62), CHAQ (0.41), and the parents (0.56) and physician (0.52) visual analogue scale. The JADI-E score is positively correlated (p&lt;0.01) with the Steinbrocker classification (0.56), the DAS 28 score (0.53), ESR (0.3) and CHAQ (0.52). <h3>Conclusions</h3> The articular and extra-articular damage JADI scores can represent a useful instrument for the monitoring of damage in children with JIA. <h3>Disclosure of Interest</h3> None declared
Chimeric Antigen Receptor 4SCAR19-Modified T Cells in Acute Lymphoid Leukemia: a Phase II Multi-Center Clinical Trial in China
Authors: Lujia Dong, Lung-Ji Chang, Zhiyong Gao, Dao-Pei Lu, Jian-Ping Zhang, Jing-Bo Wang, Le-Ping Zhang, Yu-Hong Chen, Hu-Yong Zheng, Ting Liu, Ting Niu, He Huang, Rong Liu, Heng-Xiang Wang, Li Gao, Tong-Hua Yang, Xun Lai
Journal: Blood (2015)
Changes in the Hierarchy of Risk Factors with Older Age in De-Novo Acute Myeloid Leukemia (AML).
Authors: Thomas Buchner, Wolfgang E. Berdel, Claudia Schoch, Torsten Haferlach, Hubert L. Serve, Joachim Kienast, Susanne Schnittger, Wolfgang Kern, Joelle Tchinda, Albrecht Reichle, Peter Staib, Wolf-Dieter Ludwig, Carlo Aul, Maria Cristina Sauerland, Achim Heinecke, Bernhard Josef Wormann, Wolfgang Hiddemann
Journal: Blood (2006)
THU0300 Risk Factors for Adverse Pregnancy Outcome in First-Line Treated Pregnancies in Antiphospholipid Antibodies-Positive Women According To Different Treatment Strategies: Results from Our 30 Years'Experience Pregnancy Clinic
Authors: M.G. Lazzaroni, L. Andreoli, F. Lupoli, E. Aggogeri, E. Bettiga, S. Zatti, A. Lojacono, F. Ramazzotto, M. Fredi, A. Tincani
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Antiphospholipid antibodies (aPL) are risk factors for Adverse Pregnancy Outcome (APO). The therapeutic strategy to adopt in aPL patients during pregnancy should in fact consider different clinical and serological risk factors. In addition to conventional therapy, some recent evidences suggest a possible role of hydroxychloroquine. <h3>Objectives</h3> To review our approach in first-line treated pregnancies in aPL patients in our 30 years9 experience Pregnancy Clinic (1985 -2015) to find out which clinical and serological risk factors have influenced the choice of treatments and which should be considered in the future for possible additional treatments. <h3>Methods</h3> We reviewed 120 first-treated pregnancies that were prospectively followed in our center by a multispecialistic team of Rheumatologists and Obstetricians. Patients were classified as Primary Antiphospholipid Syndrome (PAPS) according to revised criteria and as Incomplete PAPS or aPL carriers according to their clinical history or aPL status. Patients with concomitant systemic autoimmune diseases were excluded. aPL profile was defined as the combination of the 3 criteria tests for aPL (Lupus Anticoagulant, anti-cardiolipin, anti-Beta2 Glycoprotein I). APO was defined as at least one of the followings: miscarriage (&lt;10th week), fetal death (≥10th week), severe preterm delivery (≤34th week) with or without preeclampsia (PE), HELLP syndrome or perinatal death. <h3>Results</h3> The type of therapy was divided in three main categories: combination therapy with low molecular weight heparin (LMWH) and LDA (68,57%), single therapy with low dose aspirin (LDA) (31,26%) and therapy with corticosteroids plus LDA (21,18%). We collected 16 APO (13%): 11 (75%) in the category of LMWH+LDA. Analyzing APO vs. non-APO pregnancies we found no differences in variables that could predict an APO (history of thrombosis, a previous APO or a triple positive aPL profile) in any of the 3 categories (Table 1). Moreover, we found an increased rate of non criteria aPL manifestations in APO patients in LMWH+ASA category (31% vs. 4%, p:0.002; OR 2.19, 95%CI 2.20–61.6), but not in the other 2 categories of treatment. <h3>Conclusions</h3> Non-criteria aPL manifestations are a risk factor for APO ande can determine failure to conventional treatment with LMWH plus LDA during pregnancy in aPL patients regardless of clinical diagnosis, serological profile or obstetric history. These patients may represent a more severe phenotype of disease and may deserve an immunomodulatory treatment to increase the probability of success during pregnancy. <h3>Disclosure of Interest</h3> None declared
AB0222 Body Mass Index, Smoking Status and Response To Rituximab in Rheumatoid Arthritis: A Real Life Study
Authors: M.C. Gerardi, A. Batticciotto, M. Antivalle, S. Bongiovanni, R. Talotta, F. Rigamonti, V. Varisco, F. Atzeni, P. Sarzi Puttini
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Several studies have demonstrated that obesity and smoking could have a negative influence on the response to anti-TNFα in Rheumatoid Arthritis (RA). Very few data are available about the impact of body mass index (BMI) and smoking status on other biologic agents. <h3>Objectives</h3> To evaluate the influence of BMI and smoking status on response to Rituximab (RTX) in RA. <h3>Methods</h3> A total of 68 RA patients treated with RTX were included in this monocentric retrospective study. BMI was calculated at the initiation of treatment. After six months of treatment, C-reactive protein level, tender and swollen joints, change of DAS28 from baseline, rates of EULAR good response and rates of remission were evaluated. <h3>Results</h3> At baseline, the median [interquartile range] BMI was 25.04 [21.4–28.8] kg/m<sup>2</sup>. The number of patients with normal weight, overweight and obesity was 34, 22 and 12, respectively. The number of patients smokers, past smokers and never smoked was 12, 17 and 38, respectively. Baseline characteristics did not differ between the three subgroups of BMI and smoking status. After six months, the number of RA patients with DAS28 decrease ≥1.2, EULAR good response and remission was 20 (29.41%), 13 (19,11%) and 12 (17.64%), respectively. The median BMI did not differ between responders and non-responders for DAS28 decrease ≥1.2 (25.7 [22.28–28.63] vs. 24.7 [21.09–29.3], p=0.49), EULAR good response (24.22 [20.91–39.75] vs. 25.1 [21.23–28.99], p=0.96) and remission (24.08 [21.84–28.24] vs. 25.1 [21.22–29.3], p=0.81). The percentages of smokers, past smokers and never smoked did not differ between responders and non-responders for DAS28 decrease ≥1.2 (smokers 15%, past smokers 25%, never smoked 60% vs. smokers 19,15%, past smokers 25.53%, never smoked 55.32%, p=0.9), EULAR good response (smokers 15,38%, past smokers 30,77%, never smoked 53,85% vs. smokers 18,52%, past smokers 24,07%, never smoked 57,41%, p=0.87) and remission (smokers 25%, past smokers 41,67%, never smoked 33,33% vs. smokers 16.36%, past smokers 21.82%, never smoked 61.82%, p=0.18). Multivariate analysis performed on data corrected for age, sex, disease duration, concomitant treatments, and previous anti-TNFs, confirmed that BMI, body weight, and smoking status did not influence the clinical response to RTX (p&gt;0.05 for all outcome variables considered). <h3>Conclusions</h3> This monocentric evaluation of RA patients demonstrated that there is no influence of BMI and smoking status on response to RTX in RA. However, larger and prospective studies are needed to confirm these results that could be useful for the selection of biologics in obese and smokers RA patients. <h3>Disclosure of Interest</h3> None declared
Impact of STAT3 Mutations on Clinical Features and Treatment Outcomes in Large Granular Lymphocyte Leukemia
Authors: Srinivasa Reddy Sanikommu, Michael Clemente, Peter Chomczynski, Swapna Thota, Bhumika J. Patel, Aziz Nazha, Bartlomiej Przychodzen, Jaroslaw P Maciejewski
Journal: Blood (2015)
Rituximab and Stem Cell Transplantation Produces Durable Remissions in Mantle Cell Lymphoma.
Authors: Francisco J. Capote, M. J. Pascual, E. Gonzalez-Barca, J. M. Bergua, A. Jimenez, A. Romero, R. Garcia-Boyero, P. Giraldo, J. Fernandez-Calvo, J. M. Ribera, M. J. Ramirez, M. L. Amigo, M. I. Munoz, D. Caballero, M. Guinot, A. Oriol, J. M. Moraleda, L. Palomera, M. Almagro, A. Leon, A. Fernandez-deSevilla, J. L. Gil
Journal: Blood (2004)
FRI0426 Do The Validated Tools of Disease and Functional Activity in Ankylosing Spondylitis Measure fibromyalgia Symptoms?
Authors: M.N. Magrey, M.A. Khan
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Concomitant fibromyalgia syndrome is a common problem in ankylosing spondylitis (AS) and its recognition is important for optimal management of AS. There is a concern that validated tools of disease activity, function and patient reported outcomes in AS may be measuring fibromyalgia pain and symptoms in patients with concomitant AS and fibromyalgia. <h3>Objectives</h3> We studied the relationship between the validated AS measures of disease activity, functional index, and markers of inflammation and ACR fibromyalgia diagnostic criteria. <h3>Methods</h3> Study was approved by our IRB. We prospectively recruited 51 subjects ≥18 years of age with AS (meeting modified New York criteria with grade 3 or 4 sacroiliitis and high disease activity (BASDAI ≥3). Demographic and clinical data were collected and stored in Redcap data base. Various validated Questionnaires to assess disease, functional activity and patient reported outcomes in AS were administered to the patients. The frequency of FMS was determined using validated 2010 ACR diagnostic criteria for fibromyalgia [1]. The patient met the fibromyalgia criteria if (i) widespread pain index (WPI) of ≥7 &amp; symptom severity score (SS) ≥5 or WPI 3–6 &amp; SS score ≥9,(ii) symptoms were present at a similar level for at least 3 months and (iii) the pain was not attributed to AS by the clinician. ESR and CRP was measured using routine laboratory methods. Descriptive analysis included continuous variables (the mean ± SD) and the categorical variables percentage. Linear regression analysis was performed to assess the association between BASDAI, BASMI, ASDAS, Rapid 3 and fibromyalgia status <h3>Results</h3> There 34 males and 17 females with mean age of 49.8 ± 12.2; 30.6% African-Americans, 63.2% whites and 4.0% Asians, with 47.0% HLA-B27 positive, 29.4% negative and 23% unknown.18/47 (38.3%) have had acute anterior uveitis. 45% of the patients had been on TNF-α inhibitors. Mean BASDAI was 5.23 (±2.5); BASFI 4.7 (± 2.8); PGA 5.1 (±2.4); ASDAS-CRP 3.4 (±1.13); and RAPID 3 score 13.76 (± 7.21), ESR 22.4 mm/hr (±22.0) and CRP 1.3 mg/dl (±1.9).21 AS patients (41.2%) satisfied the diagnostic criteria of fibromyalgia. No statistically significant relationship was found between WPI score (Figure 1) with BASDAI (p=0.56), ASDAS (p=0.19), BASFI (0.50), RAPID 3 (p=0.70), CRP (p=0.25), and ESR (p=0.30). Also, no statistically significant relationship was found between SS score (Figure 1) with BASDAI (p=0.12), ASDAS (p=0.87), BASFI (0.73), RAPID 3 (p=0.75), CRP (p=0.79), and ESR (p=0.90). <h3>Conclusions</h3> Despite high frequency of fibromyalgia prevalence in our patients with AS and active disease, the validated tools of disease and functional activity in AS did not measure fibromyalgia pain and symptoms. <h3>Disclosure of Interest</h3> None declared
AB0481 Description of A Late-Onset Systemic Lupus Erythematosus Cohort
Authors: M. Fernández Matilla, E. Grau García, G. Poveda Marín, C. Feced Olmos, E. Labrador Sánchez, F.M. Ortiz Sanjuan, D. Hervás Marín, N. Fernández-Llanio, V. Fornes Ferrer, K. Arévalo Ruales, R. Negueroles Albuixech, J. Ivorra Cortés, J. Fragio Gil, I. Martínez Cordellat, J. Valero Sanz, I. Chalmeta Verdejo, L. González Puig, C. Alcañiz Escandell, C. Nájera Herranz, J. Castellano Cuesta, J. Román Ivorra
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The late-onset Systemic Lupus Erithematosus (SLE) has been defined as that one beginning after 50 years old, and supposes around 6–18% of the SLE patients. According to the literature, the most common clinical manifestations are interstitial lung disease, serositis, Sjögren9s syndrome and cytopenias. Though the illness activity is lower in these patients, this population usually stands with more accumulative damage and has a higher mortality than the early-onset SLE patients. <h3>Objectives</h3> To study the differences between the late-onset SLE patients and the conventional-onset ones, regarding to the debut and actual manifestations, biomarkers of autoimmunity, accumulative damage and disease activity. <h3>Methods</h3> Cross-sectional prospective study of SLE patients according to the SLICC-2012 criteria, coming from the Rheumatology Service of Arnau de Vilanova Hospital and La Fe Hospital in Valencia, Spain. All patients had a complete blood-test with autoimmunity markers, and clinical and activity data were collected using the SLICC-ACR and SELENA-SLEDAI questionnaires. <h3>Results</h3> A total of 140 patients were evaluated; (95% were women) with 33,39±13,63 year-old average at the diagnosis time with a 10,05±11,42 year-evolution of SLE. Of them, 12% had a late-onset of the disease (diagnosis at &gt;50 years old). In this group of patients we found a higher incidence of SS and Raynaud9s phenomenon as the initial symptom (5,9% and 11,8% respectively), compared to the early-onset patients (2,4% and 4,1%). However, regarding to the actual manifestations, this group has a lower incidence of Raynaud9s, as well as renal damage or cytopenias. We observe a higher proportion of SS between the late-onset group, although the ENAs levels are lower than in the early-onset group. In addition, the late-onset group has an incidence of cardiovascular events 4 times higher than the early-onset one. <h3>Conclusions</h3> We observe a concordance between the debut symptoms in our late-onset series and other series described previously in the literature, where SS presents with a higher proportion in these patients. On the other hand, we cannot distinguish if the higher proportion of cardiovascular events in this groups is due to the late-onset SLE characteristics itself, or to other factors regarding to the older age. <h3>Disclosure of Interest</h3> None declared
The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia
Authors: Eytan M. Stein, Guillermo Garcia-Manero, David A. Rizzieri, Michael Savona, Raoul Tibes, Jessica K Altman, Mojca Jongen-Lavrencic, Hartmut Döhner, Scott Armstrong, Roy M Pollock, Nigel J Waters, Michelle Legler, Blythe Thomson, Scott Daigle, Alice McDonald, Carly Campbell, Ed Olhava, Eric E Hedrick, Bob Lowenberg, Robert A Copeland, Martin S. Tallman
Journal: Blood (2014)
GM-CSF Secreting Leukemia Cell Vaccination after Allogeneic Reduced Intensity Hematopoietic Stem Cell Transplantation for Advanced Myeloid Malignancies
Authors: Vincent Ho, Glenn Dranoff, Haesook Kim, Matthew Vanneman, Mildred Pasek, Corey Cutler, John Koreth, Edwin Alyea, Joseph H Antin, Ritz Jerome, Robert J Soiffer
Journal: Blood (2008)
PTH-030 How Does Delivery of Appropriate Endotherapy at Index Endoscopy Affect Outcome in Patients with Non-Variceal Bleeding?
Authors: K Waddell, G White, A Stanley, AJ Morris
Journal: Gut (2016)

<h3>Introduction</h3> NICE recommends that patients with non-variceal acute upper gastrointestinal bleeding (AUGIB) and stigmata of recent haemorrhage (SRH) are offered endoscopic treatments (combination or mechanical method).<sup>1</sup> We audited the appropriateness and outcomes of endoscopic therapy in patients with non-variceal bleeding in a University Hospital with a dedicated consultant led out of hours endoscopy service. <h3>Methods</h3> AUGIB patients who underwent an emergency endoscopy (OGD) were identified from endoscopy, theatre and electronic records between 01.01.15 and 30.04.15. Our electronic clinical database was used to ascertain clinical details and outcomes. <h3>Results</h3> A total of 116 patients received an emergency OGD. Rebleeding occurred in 18 (15.5%) and 30 day mortality was 11%. 24 patients had non-variceal bleeding with SRH. 22 (92%) of these patients received endotherapy. Haemostasis was achieved after endotherapy in 20 (91%) patients.Two patients required CT angiography/embolization of the gastroduodenal artery. Two received no therapy. 19/24 (79%) patients received at least dual endoscopic therapy with 9/24 (37.5%) patients &gt;2 modalities. 5/24 (9%) patients did not receive minimal recommended therapy; 3 patients (13%) received single (non-mechanical) modality. 2 patients received no treatment. In patients with endoscopic therapy, haemostasis was achieved in 13/22 (59%) patients at first OGD, 5/22 (27%) at second OGD and 2 (9%) at third OGD. In the two patients who failed endoscopic therapy, haemostosis was achieved at CTA. 7/22 patients (32%) did not achieve haemostasis at index endoscopy and required repeat endoscopy. Of these patients 5 (71%) had suboptimal endoscopic therapy at index endoscopy. In the 15 patients who achieved haemostasis 3 (20%) had suboptimal therapy at index endoscopy. (p = 0.05, Fisher’s exact test) <h3>Conclusion</h3> In this audit he failure to deliver effective endoscopic therapy at the index endoscopy led to ongoing bleeding in patients with non-variceal bleeding and SRH. In this audit we found 37% of patients needed triple endoscopic therapy to achieve haemostasis. The impact of such intensive endotherapy requires further study. <h3>Reference</h3> 1 NICE: https://www.nice.org.uk/guidance/gs38 <h3>Disclosure of Interest</h3> K. Waddell: None Declared, G. White: None Declared, A. Stanley Conflict with: Cook Medical, Boston Scientific, A. Morris Conflict with: Cook Medical, Boston Scientific.
A Potent Thymic Function Is Associated with a Low Risk of Relapse In Leukemia Patients Treated with Haploidentical Stem Cell Transplantation
Authors: Emmanuel Clave, Daniela Lisini, Corinne Douay, Giovanna Giorgiani, Marc Busson, Marco Zecca, Dominique Charron, Maria E. Bernardo, Antoine Toubert, Franco Locatelli
Journal: Blood (2010)
Allogeneic Stem Cell Transplantation for CML in Accelerate or Blastic Phase
Authors: Elena V Morozova, Tatjana Zabelina, Francis Ayuk, Christine Wolschke, Thomas Stübig, Sergey N Bondarenko, Alexandr L. Alianskii, Axel R. Zander, Boris Afanasyev, Nicolaus Kröger
Journal: Blood (2014)
Low Thymic Natural Regulatory T Cell Output in the Donor Is Associated with An Increased Incidence of Extensive Chronic GvHD After T Cell Depleted Matched Sibling Stem Cell Transplantation (SCT)
Authors: Zachariah A. McIver, J. Joseph Melenhorst, Haiyun Zheng, Colin O. Wu, Andrew Grim, Sawa Ito, Irene Cho, Nancy F. Hensel, A. John Barrett
Journal: Blood (2011)
Expression of Human Telomerase Reverse Transcriptase (hTERT) Splice Variants In Chronic Lymphocytic Leukemia (CLL)
Authors: Marzia Palma, Parviz Kokhaei, Lotta Hansson, Mohammad Hojat-Farsangi, Aniruddha Raja Choudhury, Anders Osterborg, Håkan Mellstedt
Journal: Blood (2010)
Biosimilar medicines in oncology: Single-center experience with biosimilar G-CSF.
Authors: Nello Salesi, Barbara Di Cocco, Enzo Veltri
Journal: Journal of Clinical Oncology (2012)

e19501 Background: A biosimilar medicine is one with proven similarity to a reference biological product for which the patent has expired and whose active ingredient is produced or derived from a living organism. Recombinant granulocyte colony-stimulating growth factors (G-CSF) are used for the prophylaxis of febrile neutropenia. Methods: In this observational study a total of 48 patients with solid tumours were treated with biosimilar Zarzio, a new biosimilar G-CSF for 4−14 days from the day following the end of chemotherapy. The primary prophylaxis group was composed of 10 patients with breast carcinoma receiving adjuvant chemotherapy (CEF: 5-fluorouracil 600 mg/m 2 , epirubicin 100 mg/m 2 G1, cyclophosphamide 600 mg/m 2 G1, q 21 for 4 cycles à docetaxel 100 mg/m 2 G1, q 21); 17 patients with locally advanced or metastatic lung carcinoma (66% adenocarcinoma, 34% squamous) receiving 4–6 cycles of platinum-based chemotherapy; 6 patients with metastatic gastric adenocarcinoma treated with TCF (Taxotere 75 mg/m 2 , cisplatin 75 mg/m 2 , 5-fluorouracil 300 mg/m 2 by continuous 24 hour infusion for 5 days, q 21) for 4–6 cycles; 4 patients with prostate adenocarcinoma treated with Docetaxel 75 mg/m 2 G1, q 21 in 6 cycles. The secondary prophylaxis group was composed of 11 patients with colorectal adenocarcinoma (54.5% treated with adjuvant XELOX therapy: Xeloda 2000 mg/m 2 G1à14, oxaliplatin 130 mg/m 2 G1, q 21, and the remainder treated with first-line metastatic FOLFOXIRI therapy [CPT-11 165mg/m 2 G1, 5-FU 3200 mg/m 2 continuous infusion for 48 hours, oxaliplatin 85 mg/m 2 G1, q 14]). Results: Three cases of febrile neutropenia were reported: two in patients with prostate adenocarcinoma and one case in a patient with pulmonary squamous cell carcinoma and multiple secondary skeletal lesions. These patients were treated with antibiotics with resolution of the clinical picture without hospitalization after 24 hours. Conclusions: Our experience indicates that the use of biosimilar G-CSF is safe and effective at reducing neutropenic complications in patients with mixed tumors and is associated with cost savings.
Characterization of Three New Fusion Genes Generated by Disruption of PDGFRB in Eosinophilia-Associated Chronic Myeloproliferative Neoplasms
Authors: Philipp Erben, Darko Gosenca, Christoph Walz, Georgia Metzgeroth, Claudia Haferlach, Martin C. Müller, Andreas Hochhaus, Nicholas C.P. Cross, Andreas Reiter
Journal: Blood (2008)
Neutropenia and G-CSF Use In Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide Plus Dexamethasone
Authors: Haowei (Linda) Sun, Christine Massey, Elizabeth Yeboah, Donna E. Reece, Suzanne Trudel, Vishal Kukreti, Esther Masih-Khan, Andrew Winter, Christine Chen
Journal: Blood (2010)
Outcomes of Second-Line Treatment By Dasatinib in Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia Patients with and without Comorbidities
Authors: Tatyana Ionova, Tatyana Nikitina, Galina Kuchma, Elza Lomaia, Tatyana Shnaider, Elena Usacheva, Kira Kurbatova
Journal: Blood (2015)